DK1278540T3 - Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose - Google Patents

Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose

Info

Publication number
DK1278540T3
DK1278540T3 DK01945064T DK01945064T DK1278540T3 DK 1278540 T3 DK1278540 T3 DK 1278540T3 DK 01945064 T DK01945064 T DK 01945064T DK 01945064 T DK01945064 T DK 01945064T DK 1278540 T3 DK1278540 T3 DK 1278540T3
Authority
DK
Denmark
Prior art keywords
atherosclerosis
inhibitors
prevention
treatment
Prior art date
Application number
DK01945064T
Other languages
Danish (da)
English (en)
Inventor
Yolande Chvatchko
Alain Tedgui
Ziad Mallat
Original Assignee
Serono Lab
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab, Inst Nat Sante Rech Med filed Critical Serono Lab
Application granted granted Critical
Publication of DK1278540T3 publication Critical patent/DK1278540T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK01945064T 2000-05-05 2001-04-30 Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose DK1278540T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00109606 2000-05-05
PCT/EP2001/004843 WO2001085201A2 (fr) 2000-05-05 2001-04-30 Utilisation d'inhibiteurs il-18 pour le traitement et/ou la prevention de l'atherosclerose

Publications (1)

Publication Number Publication Date
DK1278540T3 true DK1278540T3 (da) 2008-07-21

Family

ID=8168631

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01945064T DK1278540T3 (da) 2000-05-05 2001-04-30 Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose

Country Status (33)

Country Link
US (1) US20040076628A1 (fr)
EP (1) EP1278540B1 (fr)
JP (1) JP5122053B2 (fr)
KR (2) KR20030016254A (fr)
CN (2) CN1841066B (fr)
AR (1) AR035640A1 (fr)
AT (1) ATE395075T1 (fr)
AU (2) AU6739001A (fr)
BG (1) BG65881B1 (fr)
BR (1) BRPI0110506B8 (fr)
CA (1) CA2407895C (fr)
CY (1) CY1110385T1 (fr)
CZ (1) CZ300792B6 (fr)
DE (1) DE60134009D1 (fr)
DK (1) DK1278540T3 (fr)
EA (2) EA007014B1 (fr)
EE (1) EE05056B1 (fr)
ES (1) ES2305082T3 (fr)
HK (2) HK1055681A1 (fr)
HR (1) HRP20020828A2 (fr)
HU (1) HU229375B1 (fr)
IL (2) IL152567A0 (fr)
ME (1) ME00554B (fr)
MX (1) MXPA02010895A (fr)
NO (1) NO329821B1 (fr)
PL (1) PL209371B1 (fr)
PT (1) PT1278540E (fr)
RS (1) RS50926B (fr)
SI (1) SI1278540T1 (fr)
SK (1) SK287761B6 (fr)
UA (2) UA87658C2 (fr)
WO (1) WO2001085201A2 (fr)
ZA (1) ZA200208228B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1257585A2 (fr) * 2000-02-10 2002-11-20 Basf Aktiengesellschaft Anticorps de liaison de l'interleukine 18 humaine et procedes de preparation et d'utilisation
EA010180B1 (ru) * 2001-01-29 2008-06-30 Лаборатуар Сероно Са Применение ингибитора il-18 для приготовления лекарственного средства для лечения и/или профилактики кардиомиопатии
BR0210007A (pt) * 2001-05-25 2004-08-10 Ares Trading Sa Uso de inibidores de il-18 para tratamento ou prevenção de lesões do sistema nervoso central
US6797727B2 (en) * 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
CA2478855C (fr) 2002-03-22 2013-12-17 Applied Research Systems Ars Holding N.V. Utilisation d'inhibiteurs de l'il-18 destines au traitement et/ou a la prevention de maladies vasculaires peripheriques
JP5171033B2 (ja) * 2003-03-11 2013-03-27 メルク セローノ ソシエテ アノニム ｍＣＭＶＩＥ２プロモーターを含んで成る発現ベクター
ES2384241T3 (es) 2003-05-13 2012-07-02 Merck Serono Sa Variantes activas de la proteína que fija IL-18 y usos médicos de las mismas
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
AU2005232436C1 (en) * 2004-04-15 2010-08-26 Athera Biotechnologies Ab Annexin V for preventing atherothrombosis and plaque rupture
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术（上海）有限公司 白介素-22的医药用途
PL1885753T3 (pl) 2005-06-03 2011-12-30 Ares Trading Sa Wytwarzanie rekombinowanego białka wiążącego IL-18
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
KR101603001B1 (ko) 2010-08-25 2016-03-11 에프. 호프만-라 로슈 아게 Il-18r1에 대한 항체 및 그의 용도
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MD707Z (ro) * 2013-01-18 2014-07-31 Институт Зоологии Академии Наук Молдовы Metodă de identificare a secvenţelor polimorfe 4a/4b ale genei sintetazei endoteliale a oxidului nitric
AU2014317035B2 (en) 2013-09-05 2020-02-27 Ab2 Bio Sa IL-18 binding protein (IL-18BP) in inflammatory diseases
CN107660150B (zh) 2015-03-05 2023-10-24 Ab2生物股份有限公司 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
CN110273591B (zh) 2019-08-13 2023-12-12 上海杉脉电子科技发展有限公司 一种单动力微型智能锁
TW202233675A (zh) 2020-10-29 2022-09-01 瑞士商諾華公司 Ｉｌ－１８拮抗劑用於治療和／或預防異位性皮炎或相關病症之用途
CN112972655A (zh) * 2021-04-16 2021-06-18 武汉大学 白细胞介素12在制备预防、缓解和/或治疗主动脉瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (fr) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Peptide artificiel capable de neutraliser l'activite biologique de l'interleukine-18
EP0987552A3 (fr) * 1998-08-31 2000-06-07 Pfizer Products Inc. Protéines de liaison pour diarylsulfonylurée
WO2000012555A1 (fr) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Proteine de liaison de l'interleukine 18

Also Published As

Publication number Publication date
EE200200620A (et) 2004-06-15
MXPA02010895A (es) 2003-03-27
CZ20023644A3 (cs) 2003-03-12
EA007014B1 (ru) 2006-06-30
CZ300792B6 (cs) 2009-08-12
HK1055681A1 (en) 2004-01-21
MEP64008A (en) 2011-12-20
WO2001085201A2 (fr) 2001-11-15
CN1434722A (zh) 2003-08-06
BG107218A (bg) 2003-06-30
JP5122053B2 (ja) 2013-01-16
HK1094909A1 (en) 2007-04-13
EA200201175A1 (ru) 2003-04-24
KR100798545B1 (ko) 2008-01-28
UA78492C2 (en) 2007-04-10
US20040076628A1 (en) 2004-04-22
HU229375B1 (en) 2013-11-28
IL152567A (en) 2010-12-30
UA87658C2 (uk) 2009-08-10
BR0110506A (pt) 2003-04-01
YU82602A (sh) 2006-01-16
SK15562002A3 (sk) 2003-05-02
ME00554B (me) 2012-03-20
EE05056B1 (et) 2008-08-15
SI1278540T1 (sl) 2008-10-31
EP1278540A2 (fr) 2003-01-29
EA200401183A1 (ru) 2004-12-30
CN1841066A (zh) 2006-10-04
AU2001267390B2 (en) 2005-09-22
PT1278540E (pt) 2008-07-03
ES2305082T3 (es) 2008-11-01
EP1278540B1 (fr) 2008-05-14
HUP0301991A3 (en) 2006-11-28
BRPI0110506B8 (pt) 2021-05-25
ZA200208228B (en) 2005-07-27
KR20070073989A (ko) 2007-07-10
NO20025307D0 (no) 2002-11-05
CA2407895A1 (fr) 2001-11-15
AR035640A1 (es) 2004-06-23
DE60134009D1 (de) 2008-06-26
HRP20020828A2 (en) 2004-12-31
CY1110385T1 (el) 2015-04-29
NO329821B1 (no) 2010-12-27
NO20025307L (no) 2002-12-18
PL365697A1 (en) 2005-01-10
JP2003532685A (ja) 2003-11-05
SK287761B6 (en) 2011-09-05
CN1841066B (zh) 2012-08-29
BRPI0110506B1 (pt) 2015-05-19
EA005410B1 (ru) 2005-02-24
PL209371B1 (pl) 2011-08-31
BG65881B1 (bg) 2010-04-30
WO2001085201A3 (fr) 2002-05-10
AU6739001A (en) 2001-11-20
CA2407895C (fr) 2012-12-18
RS50926B (sr) 2010-08-31
HUP0301991A2 (hu) 2003-09-29
CN1250286C (zh) 2006-04-12
IL152567A0 (en) 2003-05-29
ATE395075T1 (de) 2008-05-15
KR20030016254A (ko) 2003-02-26

Similar Documents

Publication Publication Date Title
DK1278540T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose
NO20032668L (no) Gyraseinhibitorer og anvendelser derav
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DK1251848T3 (da) Gyraseinhibitorer og anvendelse deraf
DK1506041T3 (da) Inbandronsyre til behandling og forebyggelse af osteoporose
DK1487541T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme
DK1133477T3 (da) Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
FI20011417A (fi) Menetelmä suojata elektroninen laite ja elektroninen laite
NO20020343L (no) Kaspase-inhibitorer og anvendelse derav
DK1427437T3 (da) Oxyntomodulin til forebyggelse eller behandling af overvægt
NO20000011D0 (no) Skumdempersammensetninger og fremgangsmåter
DK1202941T3 (da) Gipssammensætninger og beslægtede fremgangsmåder
DK1268425T3 (da) Carbamatcaspaseinhibitorer og anvendelse deraf
NO20015274L (no) ACE-2 inhiberende forbindelser og fremgangsmåter for anvendelse derav
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
IS7003A (is) Arómatisk súlfonhýdroxýamöt og notkun þeirra til tálmunar próteasa
NO20031806D0 (no) Anvendelse av pericytt apoptosehemmere for behandling og/eller forhindringav diabetisk retinopati
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
DK1337547T3 (da) Nuklease-baseret fremgangsmåde til detektion og kvantificering af oligonukleotider
DK1355668T3 (da) Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
DE60223540D1 (de) Mundschutz und mundschutzfolie
PT1274700E (pt) Di-hidrobenzopiranos di-hidrobenzotiopiranos e tetra-hidroquinolinas para o tratamento de afeccoes mediadas por cox-2
NO20055668D0 (no) Beta-amyloidinhibitorer og anvendelse derav
DK1381620T3 (da) Hypersulfaterede disaccharider og fremgangsmåder til anvendelse af samme til behandling af inflammationer
EE05263B1 (et) IL-18 inhibiitorite kasutamine keskn„rvissteemi kahjustuste raviks v?i ennetamiseks